Re-evaluating the efficacy of β-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling

Cardiovascular Research

Volumn 82, Issue 3, 2009, Pages 439-447

  Ahrens Nicklas, Rebecca C ^a   Clancy, Colleen E ^a   Christini, David J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adrenergic (ant)agonists; Arrhythmia (mechanisms); Computer modelling; Long QT syndrome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; PROPRANOLOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; GUINEA PIG; HEART CONDUCTION; HEART DEPOLARIZATION; HEART MUSCLE CELL; HEART REPOLARIZATION; LONG QT SYNDROME; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ACTION POTENTIALS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; COMPUTER SIMULATION; GUINEA PIGS; HUMANS; ISOPROTERENOL; LONG QT SYNDROME; MODELS, CARDIOVASCULAR; PHENOTYPE; PROPRANOLOL;

EID: 66249105024     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp083     Document Type: Article

References (46)

1. Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation 1991;84:503-511.
2. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103: 89-95.
3. Shimizu W, Noda T, Takaki H, Kurita T, Nagaya N, Satomi K et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003;41:633-642.
4. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616-623.
5. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292:1341-1344.
6. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
7. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-469.
8. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
9. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 1995;4:1603-1607.
10. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-811.
11. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376:683-685.
12. Priori SG, Napolitano C, Cantu F, Brown AM, Schwartz PJ. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. Circ Res 1996;78:1009-1015.
13. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000;35:778-786.
14. Nuyens D, Stengl M, Dugarmaa S, Rossenbacker T, Compernolle V, Rudy Y et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med 2001;7:1021-1027.
15. Head CE, Balasubramaniam R, Thomas G, Goddard CA, Lei M, Colledge WH et al. Paced electrogram fractionation analysis of arrhyth-mogenic tendency in DeltaKPQ Scn5a mice. J Cardiovasc Electrophysiol 2005;16:1329-1340.
16. Faber GM, Rudy Y. Action potential and contractility changes in Na+ overloaded cardiac myocytes: a simulation study. Biophys J 2000;78: 2392-2404.
17. Tarr M, Luckstead EF, Jurewicz PA, Haas HG. Effect of propranolol on the fast inward sodium current in frog atrial muscle. J Pharmacol Exp Ther 1973;184:599-610.
18. Wang DW, George AL Jr. Abstract 505: propranolol block of human cardiac sodium channels is enhanced by SCN5A mutations in long-QT syndrome type 3. Circulation 2007;116:II-88.
19. Woosley RL, Kornhauser D, Smith R, Reele S, Higgins SB, Nies AS et al. Suppression of chronic ventricular arrhythmias with propranolol. Circulation 1979;60:819-827.
20. Shah M, Akar FG, Tomaselli GF. Molecular basis of arrhythmias. Circulation 2005;112:2517-2529.
21. Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ Res 1994;74:1097-1113.
22. Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko W et al. Ionic mechanisms responsible for the electrocardiographic pheno-type of the Brugada syndrome are temperature dependent. Circ Ress 1999;85:803-809.
23. Nakamura H, Kurokawa J, Bai CX, Asada K, Xu J, Oren RV et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation 2007;116:2913-2922.
24. VerkerkAO,WildersR, deGeringelW, Tan HL. Cellular basis of sex disparities in human cardiac electrophysiology. Acta Physiol (Oxf) 2006;187:459-477.
25. Berecki G, Zegers JG, Bhuiyan ZA, Verkerk AO, Wilders R, van Ginneken AC. Long-QT syndrome-related sodium channel mutations probed by the dynamic action potential clamp technique. J Physiol (Lond) 2006;570:237-250.
26. Viswanathan PC, Shaw RM, Rudy Y. Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation 1999;99:2466-2474.
27. Gima K, Rudy Y. Ionic current basis of electrocardiographic waveforms: a model study. Circ Res 2002;90:889-896.
28. Clancy CE, Rudy Y. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature 1999;400:566-569.
29. Rudy Y. From genetics to cellular function using computational biology. Ann N YAcad Sci 2004;1015:261-270.
30. Saucerman JJ, Brunton LL, Michailova AP, McCulloch AD. Modeling beta-adrenergic control of cardiac myocyte contractility in silico. J Biol Chem 2003;278:47997-48003.
31. Choe CU, Schulze-Bahr E, Neu A, Xu J, Zhu ZI, Sauter K et al. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon. Hum Mol Genet 2006;15:2888-2902.
32. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res 2005;96:e25-e34.
33. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006;70:1575-1584.
34. Wang DW, Yazawa K, Makita N, George AL Jr, Bennett PB. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 1997;99: 1714-1720.
35. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 2007;292:H66-H75.
36. Shaw RM, Rudy Y. Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ Res 1997;81:727-741.
37. Diness JG, Hansen RS, Nissen JD, Jespersen T, Grunnet M. Antiarrhythmic effect of IKr activation in a cellular model of LQT3. Heart Rhythm 2009; 6:100-106.
38. Gelzer AR, Koller ML, Otani NF, Fox JJ, Enyeart MW, Hooker GJ et al. Dynamic mechanism for initiation of ventricular fibrillation in vivo. Circulation 2008;118:1123-1129.
39. Henry H, Rappel WJ. The role of M cells and the long QT syndrome in cardiac arrhythmias: simulation studies of reentrant excitations using a detailed electrophysiological model. Chaos 2004;14:172-182.
40. Chinushi M, Izumi D, Iijima K, Ahara S, Komura S, Furushima H et al. Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome. Europace 2008;10:249-255.
41. Salama G, London B. Mouse models of long QT syndrome. J Physiol (Lond) 2007;578:43-53.
42. Thomas G, Killeen MJ, Grace AA, Huang CL. Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome. aActa Physiol (Oxf) 2008;192:505-517.
43. Duff HJ, Roden DM, Brorson L, Wood AJ, Dawson AK, Primm RK et al. Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol 1983;2:1134-1140.
44. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med 1993;328:303-307.
45. Ben Caref E, Boutjdir M, Himel HD, El-Sherif N. Role of subendocardial Purkinje network in triggering torsade de pointes arrhythmia in experimental long QT syndrome. Europace 2008;10: 1218-1223.
46. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 2006;92(Suppl. 4):iv1-iv5.